The contribution of the
Choline
Lipids
Magnetic resonance imaging
Proton magnetic resonance spectroscopy
Uterine cervical neoplasms
Journal
European radiology experimental
ISSN: 2509-9280
Titre abrégé: Eur Radiol Exp
Pays: England
ID NLM: 101721752
Informations de publication
Date de publication:
03 10 2022
03 10 2022
Historique:
received:
01
04
2022
accepted:
02
08
2022
entrez:
2
10
2022
pubmed:
3
10
2022
medline:
5
10
2022
Statut:
epublish
Résumé
The aim of this study was to investigate the role of the lipid peak derived from We enrolled 17 patients with histologically proven cervical cancer who underwent 3-T MR imaging at baseline. In addition to conventional imaging sequences for pelvic assessment, the protocol included a single-voxel point-resolved spectroscopy (PRESS) sequence, with repetition time of 1,500 ms and echo times of 28 and 144 ms. Spectra were analysed using the LCModel fitting routine, thus extracting multiple metabolites, including lipids (Lip) and total choline (tCho). Patients with LACC were treated with NACT and reassessed by MRI at term. Based on tumour volume reduction, patients were classified as good responder (GR; tumour volume reduction > 50%) and poor responder or nonresponder (PR-or-NR; tumour volume reduction ≤ 50%). Of 17 patients, 11 were LACC. Of these 11, only 6 had both completed NACT and had good-quality Assessment of lipid peak at
Sections du résumé
BACKGROUND
The aim of this study was to investigate the role of the lipid peak derived from
METHODS
We enrolled 17 patients with histologically proven cervical cancer who underwent 3-T MR imaging at baseline. In addition to conventional imaging sequences for pelvic assessment, the protocol included a single-voxel point-resolved spectroscopy (PRESS) sequence, with repetition time of 1,500 ms and echo times of 28 and 144 ms. Spectra were analysed using the LCModel fitting routine, thus extracting multiple metabolites, including lipids (Lip) and total choline (tCho). Patients with LACC were treated with NACT and reassessed by MRI at term. Based on tumour volume reduction, patients were classified as good responder (GR; tumour volume reduction > 50%) and poor responder or nonresponder (PR-or-NR; tumour volume reduction ≤ 50%).
RESULTS
Of 17 patients, 11 were LACC. Of these 11, only 6 had both completed NACT and had good-quality
CONCLUSIONS
Assessment of lipid peak at
Identifiants
pubmed: 36184731
doi: 10.1186/s41747-022-00300-1
pii: 10.1186/s41747-022-00300-1
pmc: PMC9527268
doi:
Substances chimiques
Lipids
0
Choline
N91BDP6H0X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Informations de copyright
© 2022. The Author(s) under exclusive licence to European Society of Radiology.
Références
Cell Mol Life Sci. 2016 Jan;73(2):377-92
pubmed: 26499846
Eur Radiol. 2019 Dec;29(12):6940-6952
pubmed: 31172275
Lancet. 2020 Feb 22;395(10224):575-590
pubmed: 32007141
J Magn Reson Imaging. 2004 Mar;19(3):356-64
pubmed: 14994305
Invest Radiol. 2019 Dec;54(12):767-773
pubmed: 31356383
Eur J Radiol. 2010 Feb;73(2):352-6
pubmed: 19084363
Br J Radiol. 2021 Sep 01;94(1125):20210054
pubmed: 34111974
Cell Metab. 2020 Jan 7;31(1):62-76
pubmed: 31813823
Magn Reson Med. 1993 Dec;30(6):672-9
pubmed: 8139448
Gynecol Oncol. 2010 Feb;116(2):253-61
pubmed: 20109726
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Dis Markers. 2020 Jul 27;2020:7415056
pubmed: 32802215
J Magn Reson B. 1994 Jun;104(2):135-42
pubmed: 8049866
Diagn Interv Radiol. 2016 Jan-Feb;22(1):75-89
pubmed: 26712681
Rofo. 2020 Oct;192(10):937-944
pubmed: 32731266
Cell Rep. 2022 May 31;39(9):110870
pubmed: 35649368
BJR Open. 2019 Jul 02;1(1):20180040
pubmed: 33178927
NMR Biomed. 2019 Oct;32(10):e4054
pubmed: 30633389
Magn Reson Imaging Clin N Am. 2016 Nov;24(4):671-686
pubmed: 27742109
J Magn Reson Imaging. 2019 Oct;50(4):1033-1046
pubmed: 30848037
Radiol Med. 2016 Nov;121(11):838-846
pubmed: 27372708
Magn Reson Med Sci. 2010;9(4):167-75
pubmed: 21187685
Eur Radiol. 2021 Oct;31(10):7802-7816
pubmed: 33852049
AJR Am J Roentgenol. 2015 Jun;204(6):W724-30
pubmed: 26001263
NMR Biomed. 2012 Apr;25(4):632-42
pubmed: 22020805
BJOG. 2009 Jan;116(2):300-3
pubmed: 19076962
Nat Rev Cancer. 2011 Nov 17;11(12):835-48
pubmed: 22089420
NMR Biomed. 2004 Feb;17(1):1-9
pubmed: 15011245
Am J Clin Oncol. 2001 Oct;24(5):522-9
pubmed: 11586108
Magn Reson Imaging Clin N Am. 2016 Feb;24(1):57-86
pubmed: 26613876
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Gynaecol Obstet. 2019 Apr;145(1):129-135
pubmed: 30656645
Radiology. 1993 Sep;188(3):791-6
pubmed: 8351349
NMR Biomed. 2019 Jan;32(1):e4015
pubmed: 30376201